secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scienture Holdings, Inc. (SCNX)
CIK:        0001382574
Form:       8-K
Filed at:   2026-08-20T20:05:32+00:00
Accession:  0001493152-26-039474
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SCNX Q2 2026: Revenue up ~510% sequentially; net loss narrows 58% YoY
---------------------------------------------------------------------

- Revenue $343,639 in Q2 2026, up ~510% from $56,325 in Q1 2026; H1 revenue $399,964 vs $10,258 in H1 2025.
- Net loss narrowed ~58% YoY to ~$2.8M; EPS improved to -$0.07 from -$0.48; operating loss ~$2.7M, down ~48%.
- Cash, equivalents and restricted cash ~$11.2M at June 30, 2026, vs ~$6.7M at Dec 31, 2025; gross margin ~97.7%.
- Commenced commercial launch of REZENOPY (naloxone nasal spray); second patent granted through 2041.
- Arbli expanded payer coverage adding ~12.5M covered lives; third patent granted; targeting profitability in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382574/000149315226039474/0001493152-26-039474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382574/000149315226039474/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-039474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer